Appendix A

Bradford Heart Failure Nurse Specialist Service

Medical Therapy Protocol

TO BE REUISED.

<u>Debbie Clegg</u>

<u>Mary Crawshaw-Ralli</u>

<u>Anne Williams</u>

<u>Issue 1</u> September 2002

Introduction

These guidelines are to be used by the Heart Failure Nurse Specialist (HFNS) under the supervision of the patient's general practitioner (GP) and the GP Specialist / cardiologist / hospital consultant.

The protocols have been devised following guidelines used by Blue (2001) within the Glasgow heart failure service and as discussed by McMurray et al (2001). They have also been discussed and agreed at a joint meeting with GP Specialist, Cardiology and Care of the Elderly consultant representation.

They include detailed protocols for the use of evidence based treatments as recommended by PACE (Promoting Action on Clinical Effectiveness in Airedale and Bradford) for patients with chronic heart failure caused by left ventricular systolic dysfunction. As outlined in the protocols, certain treatments must be discussed with the patient's GP (ACE inhibitors, spironolactone, digoxin) or the contact cardiologist / physician / GP Specialist (beta-blockers) prior to any change.

The first line of contact will usually be the patients own GP. The HFNS may then act as an intermediary if required and seek advice about treatment from the GP Specialist / identified GP in the PCT with a special interest in cardiology. If further clarification or advice is required the patients hospital consultant will be contacted.

All changes in treatment will be communicated via locally agreed method (telephone / fax / written report) to relevant parties (GP, hospital and community personnel involved in the continued care) and recorded in the HFNS case records and patient-held cardiac record.

The protocols will receive multidisciplinary review at a minimum of 6 monthly intervals and be updated accordingly.


Increasing Loop Diuretic

Sudden increase in weight (>1Kg above dry weight [patients stable weight with no signs of fluid overload] sustained over ≥ 2 days) especially if accompanied by oedema and breathlessness - titrate as below. **Frusemide** 40mg od — → 80mg od → 80mg mane 80mg od -40mg lunch 80mg mane —→ 80mg mane 80 mg lunch 40mg lunch 80mg mane → seek advice from GP 80mg lunch (NB If patient on bumetanide then as above but 40mg frusemide equivalent to 1mg bumetanide) Maintain increased dose for 3 days Assess via phone call / visit If weight increased If dry weight not achieved but If dry weight achieved -Seek advice from GP Continuing to loose weight then return to original dose Reassess in a further 3-4 days. If dry weight still not achieved Then seek advice from patients GP As first line contact.

NB HFNS will only make <u>one</u> incremental change before seeking advice from GP→Specialist GP→consultant

GP and patients own consultant to receive faxed report following treatment changes

Decreasing Loop Diuretic



Initiation and use of thiazide diuretics and metolazone

Initiation will be via GP or hospital consultant (facilitated by HFICS).

When thiazide / metolazone is combined with loop diuretics patients urea and electrolytes (U+E's) will be checked weekly for the first 4 weeks and monthly thereafter if stable and no change in therapy or condition.

Advice will be sought if U+Es are outside normal range (see Blood chemistry monitoring – diuretics section).

If patient is showing signs of fluid depletion on combined therapy then thiazide / metolazone would be reduced / discontinued initially (following discussion with GP) followed by reduction in loop diuretic as per protocol if required.

Initiation and use of spironolactone

Therapy should only be commenced after discussion with patient's GP and cardiologist

Indication - Patients who remain symptomatic (NHYA classification For IV) despite treatment with an ACE inhibitor and diuretic(s) and where indicated a beta blocker

K+ supplements and K+ sparing diuretics should be discontinued
 2 weeks prior to spironolactone being commenced.
 Loop diuretics should be used as an alternative during this time
 Cautions and contra-indications will be assessed

Baseline U+Es will be checked prior to initiation

lf: •Creat >200 µmol •Urea >11.2 mmol

Seek specialist advice

•K >4.5 mmol

lf:

•Creat <200 µmol •Urea<11.2 mmol •K<4.5 mmol

Commence therapy at 25mg od (lower if concern) Target dose 25-50mg od

U+Es will be checked 1 week after initiation

If:

•Creat≽250µmol / increase by 25% from baseline •Urea≽18mmol / increase by 50% from baseline •K≽5.5mmol

•Diarrhoea / vomiting or any other cause of sodium and water loss

Stop therapy and contact GP Spironolactone or loop diuretics may need decreasing lf:

Creat <250umol / no increase by 25% from baseline
Urea <18mmol / no increase by 50% from baseline
K <5.5mmol
No diarrhoea/vomiting

Continue treatment and monitor
U+Es 4,8+12 weeks; 6,9+12 months;
6 monthly thereafter, stopping / reducing
treatment as per protocol if necessary

Blood Chemistry Monitoring - diuretics

A base line measurement of U+Es will be taken on first home visit, unless measured in previous 48 hours with no change in therapy or condition Increase in diuretic therapy for more than 1 week Re-check U+Es within 7-14 days after increase Urea≽15 mmols or increased by >50% from baseline K≽5.5mmols K≤3.5mmols and/or Creat>200µmol or increased by >50% from baseline Seek immediate (within same working day) advice from GP in first instance

Other Blood monitoring

Test	Responsibility	Time scale
Full blood count	Heart failure nurse while under their care. Long term -CHD lead/support team or district nurse	Annually unless clinically indicated
Urea and creatinine + Electrolytes	Heart failure nurse while under their care. Long term -CHD lead/support team or district nurse	As per protocols initially then 6 monthly
Glucose	Heart failure nurse first sample. Long term -CHD lead/support team or district nurse	Annually
Serum cholesterol	Heart failure nurse while under their care. Long term -CHD lead support team or district nurse	Annually once statin therapy stable
Liver enzymes, bilirubin	Heart failure nurse while under their care. Long term -CHD lead/support team or district nurse.	Annually unless clinically indicated
Albumin	Heart failure nurse while under their care. Long term CHD lead/support team or district nurse	As clinically indicated
Thyroid function	Heart failure nurse while under their care. Long term CHD lead/support team or district nurse	As clinically indicated
Digoxin levels	Heart failure nurse while under their care. Long term CHD lead/support team or district nurse	As clinically indicated

Initiation and use of Ace Inhibitors

Initiation will be via GP or hospital consultant
Cautions and contraindications (history of angio-oedema, significant renovascular
disease / aortic stenosis) will be checked

	Starting dose	Incremental rise	Target dose					
Preferred of		2 Ema	10mg od					
Ramipril	2.5mg od	2.5mg	ronig od					
Lisinopril	2.5-5mg od	2.5mg	30mg od					
Some alternatives								
Captopril	6.25mg tds	2nd dose 12.5mg tds then in 12.5mg increments	50-100mg tds					
Enalapril	2.5mg bd	2.5mg	10-20mg bd					

BP and U+Es will be checked within 10 days following each increase There will be a minimum of 7 days between each increase

If:

Symptomatic hypotension
 Asymptomatic hypotension (systolic BP <90mmg)

- Creat≥200 µmol or >50% from baseline
- urea>15 mmols or >50% from baseline
 K >5mmol

Seek specialist advice

If:

No symptomatic hypotensionNo asymptomatic hypotensionNo renal impairment

Continue up titration until target dose achieved

NB at any time during initiation of ACE in all patients ACE will be stopped and advice sought from GP if:

- K rises to ≥ 6mmol
- Urea rises to≥15mmol
- creat rises to ≥ 200 µmol

Initiation and use of Angiotensin II receptor antagonists

To be used only if patient is truly intolerant of an ACE inhibitor due to persistent cough.

Prior to initiation and on increasing U+Es and blood pressure will be checked (see ACE inhibitor protocol for values)

Preferred choice of drug is Valsartan (only All antagonist at present with data in heart failure). The starting dose is 80mg od (40mg in those over 75 years or with other cautions). This can be increased to 160 od (80mg for those with hepatic impairment) after 4 weeks.

Alternatives that may be seen are Candesartan, Irbesartan and Losartan.

Initiation and Use of Beta Blockers

To be commenced under specialist supervision only*

Patients whose heart failure is stable (no admission into hospital in the last month, no alteration in therapy in last 2 weeks) and who are taking maximum standard therapy (ACE and possibly digoxin) will be referred to specialist* for initiation.

Patients who do not meet these criteria but may benefit from therapy will be referred to the cardiologist for review

Cautions and contra-indications will be checked.

Starting dose		Incremental rises				Maintenance dose
<u>Week</u>	<u>1</u>	<u>2</u>	<u>3</u>	<u>5</u>	<u>8</u>	<u>12</u>
Bisoproloi (od)	1.25mg	2.5mg	3.75mg	5.0mg	7.5mg	10mg
<u>Week</u>	<u>1</u>		<u>4</u>	<u>6</u>		<u>8</u>
Carvedilol (bd)	3.125mg		6.25mg	12.5 r	•	25mg atients >85Kg - 50mg)

NB Intervals given are a minimum level and progression may be slower if necessary

Patients will be assessed within 4 days (phone or visit)

If:

Decrease in heart rate <50bpm
 Symptomatic hypotension
 Asymptomatic hypotension (BP<90systolic)
 Evidence of respiratory
 problem but no weight gain

Seek advice from initiating physician

NB Beta blockers will not be stopped without prior consent If:

No decrease in heart rate
 No symptomatic hypotension
 No asymptomatic hypotension
 Continue up titration

If significant weight gain and shortness of breath see diuretic protocol

Improvement - continue up titration

No improvement seek advice from specialist*

^{*} Specialist supervision = Specialist GP / Cardiologist / General Physician / Care of the Elderly Physician

Digoxin

Therapy will be initiated by patients GP or under consultant advice facilitated by HFNS. Cautions and contraindications will be assessed.

Consider patients:

in sinus rhythm with symptomatically severe heart failure
 (NYHA class III or IV) despite optimal therapy (diuretics and ACEI);
 recurrent hospital admissions for heart failure
 in atrial fibrillation who are not suitable for beta-blockers

Check digoxin levels if:

digoxin toxicity is suspected (nausea + vomiting, headache, confusion, visual symptoms, arrhythmias -AV block, VT, AV junctional rhythms, atrial tachycardia) (NB patient with signs of toxicity can show levels within normal limits)
patient is commenced on other drugs which are known to alter levels e.g. erythromycin, amiodarone
patient has poor or worsening renal function

Blood potassium concentrations should be monitored and hypokalaemia avoided.

Non-heart failure medications

Patients with heart failure are usually elderly and have concomitant cardiovascular and non-cardiovascular problems for which they receive treatment. A number of commonly used drugs may lead to clinical deterioration of neart failure.

The HFNS will assess for medications that may exacerbate heart failure or interact with usual medication in particular:

- 'over the counter' drugs especially NSAIDs, high dose aspirin, St John's Wort, liquorice and some herbal and homeopathic remedies
- most calcium channel antagonists (except amlodipine, felodipine which should be used only for angina or uncontrolled hypertension).
- corticosteriods by causing sodium and water retention
- tricyclic antidepressant drugs may depress cardiac function and have pro-arrhythmic effect.
- •care with patients on lithium as levels can be affected by changes in diuretic doses. For patients on lithium the levels should be checked each time U+Es are done.
- •Erythromycin and some antifungal agents prolongation of QT interval; may precipitate ventricular arrythmias
- •Terfenadine and other anti histamines blockade of potassium channel and prolongation of QT interval; may precipitate ventricular arrhythmias especially if given with erythromycin and antifungal agents eg ketoconazole and mibefradil
- •ensure side effects / interactions of any new drugs are checked in BNF prior to commencement

Advice for patients

The HFNS will be giving advice to patients and their carers about several aspects of heart failure including medication and lifestyle as detailed below. The BHF booklet 'Medicines for the Heart' will be used to supplement any information given.

Diuretic therapy

- Timing need not be fixed for loop diuretics (eg could postpone morning dose until after shopping trip), however it is better to avoid taking after 4-6pm as this can lead to nocturia.
- There is little advantage in moving the time of dosing for thiazides and metazolone as they are long acting.
- Report dizziness / light-headedness as this may indicate overtreatment.
- Advise caution in hot weather (risk of dehydration) and ensure adequate fluid intake.
- Report diarrhoea and/or vomiting (more than 2 episodes in 24 hours) to HFNS / GP / practice nurse
- Report sudden, sustained weight loss / gain (more than 1kg over 3 days) to HFNS / GP / practice nurse.
- Report other symptoms of fluid overload ie increasing breathlessness, frothy sputum, peripheral oedema, to HFNS / GP / practice nurse asap.

Ace-inhibitor therapy

- Report any dizziness // blackouts / light-headedness to HFNS / GP / practice nurse.
- Report angioedema to HFNS / GP / practice nurse.
- Stress importance of having biochemistry and blood pressure checked during titration and at least annually thereafter.
- Advise to take first dose at night.
- Advise of other possible side effects ie persistant dry cough, rash, GI symptoms, upper respiratory symptoms (sinusitis, rhinitis, sore throat)

Angiotension II receptor antagonists

Same advice as above with the exception of warning about cough

Beta blockers

- Advise that beta-blocker should help heart failure in long term therefore no immediate symptomatic improvement expected.
- Advise patient they may experience initial, temporary worsening of heart failure symptoms eg weight gain,†breathlessness,†oedemand to report to HFNS / GP / practice nurse so that other medication (particularly diuretic) may be altered.
- Advise to report any other side effects in particular problems with dizziness / light-headedness / syncope or bronchospasm and fatigue, which could indicate hypotension or bradycardia.
- Advise on other common, potential side-effects ie cold peripheries, impotence, sleep disturbances

Spironolactone

- Advise to report any illness or circumstances that may cause fluid depletion eg. diarrhoea and / or vomiting, excessive perspiring, reduced / no fluid intake to HFNS / GP / practice nurse.
- Advise to report any postural dizziness / light-headedness / syncope, significant and sustained weight loss (1kg over 3 days), confusion, cramps, muscle weakness (may indicate fluid depletion / electrolyte imbalance) to HFNS / GP / practice nurse
- Advise of other common, potential side effects ie impotence, GI disturbance, gynaecomastia, menstrual irregularities
- Reiterate importance of having blood chemistry regularly checked.

Digoxin

- Advise of any side effects that may indicate digoxin toxicity ie nausea and vomiting, anorexia, yellow tint to vision (xanthopsia), confusion, falls (esp. in elderly) and to report to HFNS / GP / practice nurse.
- Importance of having levels checked if certain other medications are commenced in particular amiodarone, erythromycin

'Over the counter' drugs

Advise to inform HFNS / GP / practice nurse / pharmacist prior to taking any 'over the counter' drugs as they may worsen heart failure especially NSAIDs, larger doses of aspirin, St John's Wort (may interact with digoxin and warfarin), some herbal and homeopathic remedies

Immunisation

All patients should be advised to have a once-only pneumococcal immunisation and annual influenza immunisation.

Lifestyle advice

Diet

- Patients will be advised to reduce their salt intake from added salt and processed food.
- A cardioprotective diet will also be advised with emphasis placed on eating 5 portions of fruit or vegetables a day and oily fish 2-3 times per week. NB. specialist dietetic advice will be sought as necessary for those patients who are underweight (BMI <20), cachexic or overweight (BMI >25), or with special dietary needs eg renal diet.
- Some patients may benefit from a fluid restriction (1-1.5L on discussion with medical staff) and this will be explained and encouraged where appropriate.

Alcohol

- Patients will be advised that an excessive intake of alcohol can exacerbate their symptoms so they should stay within recommended limits (14 units/week for women, 21 units / week for men, with at least 2 alcohol free days/ week).
- Patients will also be advised to avoid binge drinking.
- Patients with alcohol related dilated cardiopymopathy will be advised to abstain from alcohol.

Exercise

- Patients with heart failure can benefit from exercise.
- Exercise will be discussed and patients will be advised to take-up or continue with some form of aerobic exercise within their capabilities eg walking, swimming
- The ultimate aim is to take 30 minutes aerobic exercise 5x per week, however any increase in activity will beneficial.
- The importance of safety will be stressed with patients advised to exercise to the point of being 'comfortably out of breath' (ie. breathless but still able to speak in sentences).
- For those with angina advice about management of chest pain and use of GTN spray will be given
- Referral to heart failure exercise programme will be made as appropriate once classes in progress

Smoking

- Basic smoking cessation advice and information will be available for patients who smoke.
- They will be assessed regarding their stage of change and readiness to try and stop.
- Referral to specialist smoking cessation service will be made as appropriate for those patients wishing to make a quit attempt.